Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| A2581138 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine whether Lipitor reduces stroke, compared to placebo in patients who have had a previous stroke or transient ischemic attack.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| atorvastatin | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Time to occurrence of fatal or non-fatal stroke |
| Measure | Description | Time Frame |
|---|---|---|
| Time to occurrence of an acute coronary event, consisting of cardiac death, nonfatal myocardial infarction, resuscitated cardiac arrest or unstable angina. | ||
| Time to occurrence of a cerebrovascular event, defined as fatal or nonfatal stroke or TIA. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | East Gosford | New South Wales | 2250 | Australia | ||
| Pfizer Investigational Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 16899775 | Result | Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):549-59. doi: 10.1056/NEJMoa061894. | |
| 38939496 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Randwick, Sydney |
| New South Wales |
| 2031 |
| Australia |
| Pfizer Investigational Site | Footscray | Victoria | 3011 | Australia |
| Pfizer Investigational Site | Heidelberg Heights | Victoria | 3081 | Australia |
| Pfizer Investigational Site | Parkville | Victoria | 3050 | Australia |
| Pfizer Investigational Site | Prahran | Victoria | 3181 | Australia |
| Pfizer Investigational Site | Perth | Western Australia | 6000 | Australia |
| Pfizer Investigational Site | Graz | A-8036 | Austria |
| Pfizer Investigational Site | Innsbruck | A-6020 | Austria |
| Pfizer Investigational Site | Vienna | 1160 | Austria |
| Pfizer Investigational Site | Villach | A-9504 | Austria |
| Pfizer Investigational Site | Ghent | 9000 | Belgium |
| Pfizer Investigational Site | Leuven | 3000 | Belgium |
| Pfizer Investigational Site | Tielt | 8700 | Belgium |
| Pfizer Investigational Site | Waregem | 8790 | Belgium |
| Pfizer Investigational Site | Porto Alegre | Rio Grande do Sul | 90610-000 | Brazil |
| Pfizer Investigational Site | São Paulo | São Paulo | 05403-000 | Brazil |
| Pfizer Investigational Site | Viña del Mar | Chile |
| Pfizer Investigational Site | Brno | 65691 | Czechia |
| Pfizer Investigational Site | Ostrava | 70384 | Czechia |
| Pfizer Investigational Site | Ostrava-Poruba | 70852 | Czechia |
| Pfizer Investigational Site | Pilsen | 30599 | Czechia |
| Pfizer Investigational Site | Prague | 14021 | Czechia |
| Pfizer Investigational Site | ZlÃn | 76275 | Czechia |
| Pfizer Investigational Site | Copenhagen Nv | 2400 | Denmark |
| Pfizer Investigational Site | Glostrup Municipality | 2600 | Denmark |
| Pfizer Investigational Site | Hellerup | 2900 | Denmark |
| Pfizer Investigational Site | Hus, Helsinki | 00029 | Finland |
| Pfizer Investigational Site | Kotka | 48210 | Finland |
| Pfizer Investigational Site | Kuopio | 70210 | Finland |
| Pfizer Investigational Site | Lahti | 15850 | Finland |
| Pfizer Investigational Site | Lappeenranta | 53130 | Finland |
| Pfizer Investigational Site | Oulu | 90220 | Finland |
| Pfizer Investigational Site | Saint-Denis | Cedex 1 | 93205 | France |
| Pfizer Investigational Site | Paris | Cedex 20 | 75970 | France |
| Pfizer Investigational Site | Toulouse | Cedex 3 | 31059 | France |
| Pfizer Investigational Site | Bourg-en-Bresse | Cedex | 01012 | France |
| Pfizer Investigational Site | Besançon | 25030 | France |
| Pfizer Investigational Site | Marseille | 13385 | France |
| Pfizer Investigational Site | Nice | 06000 | France |
| Pfizer Investigational Site | Paris | 75018 | France |
| Pfizer Investigational Site | Bad Rodach | 96476 | Germany |
| Pfizer Investigational Site | Berlin | 10117 | Germany |
| Pfizer Investigational Site | Essen | 45122 | Germany |
| Pfizer Investigational Site | Heidelberg | Germany |
| Pfizer Investigational Site | Leipzig | 04103 | Germany |
| Pfizer Investigational Site | Mannheim | 69135 | Germany |
| Pfizer Investigational Site | Minden | 32427 | Germany |
| Pfizer Investigational Site | München | 81377 | Germany |
| Pfizer Investigational Site | München | 81545 | Germany |
| Pfizer Investigational Site | München | 81675 | Germany |
| Pfizer Investigational Site | Münster | 48149 | Germany |
| Pfizer Investigational Site | Regensburg | 93053 | Germany |
| Pfizer Investigational Site | Athens | Melissia | 15127 | Greece |
| Pfizer Investigational Site | Athens | 11527 | Greece |
| Pfizer Investigational Site | Athens | 15127 | Greece |
| Pfizer Investigational Site | Thessaloniki | 54636 | Greece |
| Pfizer Investigational Site | Thessaloniki | 57010 | Greece |
| Pfizer Investigational Site | Haifa | 34362 | Israel |
| Pfizer Investigational Site | Holon | 58100 | Israel |
| Pfizer Investigational Site | Petah Tikva | 49372 | Israel |
| Pfizer Investigational Site | Tel Aviv | Israel |
| Pfizer Investigational Site | Via Brunamonti 15 | Perugia | 06122 | Italy |
| Pfizer Investigational Site | Bari | 70124 | Italy |
| Pfizer Investigational Site | Bergamo | 24128 | Italy |
| Pfizer Investigational Site | Genova | 16132 | Italy |
| Pfizer Investigational Site | Milan | 20132 | Italy |
| Pfizer Investigational Site | Monza | 20052 | Italy |
| Pfizer Investigational Site | Monterrey | Nuevo León | 64460 | Mexico |
| Pfizer Investigational Site | Rotterdam | Gelderland | 3015 | Netherlands |
| Pfizer Investigational Site | Almelo | 7609 PP | Netherlands |
| Pfizer Investigational Site | Delft | 2625 AD | Netherlands |
| Pfizer Investigational Site | Goes | 4462 RA | Netherlands |
| Pfizer Investigational Site | RB Groningen | 9700 | Netherlands |
| Pfizer Investigational Site | Tilburg | 5022 GC | Netherlands |
| Pfizer Investigational Site | Takapuna | Auckland | New Zealand |
| Pfizer Investigational Site | Auckland | New Zealand |
| Pfizer Investigational Site | Christchurch | New Zealand |
| Pfizer Investigational Site | Bialystok | 15-276 | Poland |
| Pfizer Investigational Site | Krakow | 31-503 | Poland |
| Pfizer Investigational Site | Lublin | 20-954 | Poland |
| Pfizer Investigational Site | Poznan | 30-355 | Poland |
| Pfizer Investigational Site | Sosnowiec | 41-200 | Poland |
| Pfizer Investigational Site | Warsaw | 01-211 | Poland |
| Pfizer Investigational Site | Warsaw | 02 - 957 | Poland |
| Pfizer Investigational Site | Wroclaw | 50-420 | Poland |
| Pfizer Investigational Site | Coimbra Codex | 3049 | Portugal |
| Pfizer Investigational Site | Lisbon | 1600 | Portugal |
| Pfizer Investigational Site | Porto | 4000 | Portugal |
| Pfizer Investigational Site | Bratislava | 81369 | Slovakia |
| Pfizer Investigational Site | Bratislava | 83301 | Slovakia |
| Pfizer Investigational Site | Bloemfontein | 9301 | South Africa |
| Pfizer Investigational Site | Cape Town | 7800 | South Africa |
| Pfizer Investigational Site | Parow | 7505 | South Africa |
| Pfizer Investigational Site | Alicante | Alicante | 03010 | Spain |
| Pfizer Investigational Site | Barcelona | Barcelona | 08035 | Spain |
| Pfizer Investigational Site | Barcelona | Barcelona | 08036 | Spain |
| Pfizer Investigational Site | L'Hospitalet (bcn) | Barcelona | 08907 | Spain |
| Pfizer Investigational Site | Burgos | Burgos | 09005 | Spain |
| Pfizer Investigational Site | Girona | Girona | 17007 | Spain |
| Pfizer Investigational Site | Madrid | Madrid | 28006 | Spain |
| Pfizer Investigational Site | Madrid | Madrid | 28040 | Spain |
| Pfizer Investigational Site | Madrid | Madrid | 28046 | Spain |
| Pfizer Investigational Site | Málaga | Malaga | 29010 | Spain |
| Pfizer Investigational Site | Seville | Sevilla | 41009 | Spain |
| Pfizer Investigational Site | Seville | Sevilla | 41013 | Spain |
| Pfizer Investigational Site | Seville | Sevilla | 41014 | Spain |
| Pfizer Investigational Site | Valencia | Valencia | 46009 | Spain |
| Pfizer Investigational Site | Zaragoza | Zaragoza | 50009 | Spain |
| Pfizer Investigational Site | Palma de Mallorca | 07014 | Spain |
| Pfizer Investigational Site | Danderyd | 18288 | Sweden |
| Pfizer Investigational Site | Stockholm | 11281 | Sweden |
| Pfizer Investigational Site | Stockholm | 17176 | Sweden |
| Pfizer Investigational Site | Umeå | 90185 | Sweden |
| Pfizer Investigational Site | Uppsala | 75185 | Sweden |
| Pfizer Investigational Site | Västervik | 59381 | Sweden |
| Pfizer Investigational Site | Aarau | 5001 | Switzerland |
| Pfizer Investigational Site | Basel | 4031 | Switzerland |
| Pfizer Investigational Site | Bern | 3010 | Switzerland |
| Pfizer Investigational Site | Lausanne | 1011 | Switzerland |
| Pfizer Investigational Site | Zurich | 8091 | Switzerland |
| Pfizer Investigational Site | Dundee | Scotland | DD1 9SY | United Kingdom |
| Pfizer Investigational Site | Newport | South Wales | NP20 4SZ | United Kingdom |
| Pfizer Investigational Site | Aberdeen | AB25 2ZN | United Kingdom |
| Pfizer Investigational Site | Cardiff | CF4 4XW | United Kingdom |
| Pfizer Investigational Site | Glasgow | G11 6NT | United Kingdom |
| Pfizer Investigational Site | Liverpool | L9 7AL | United Kingdom |
| Pfizer Investigational Site | Nottingham | NG5 1PB | United Kingdom |
| Pfizer Investigational Site | Woolwich | SE18 4HQ | United Kingdom |
| Pfizer Investigational Site | Caracas | 1041 | Venezuela |
| Chemello K, Gallo A, Guedon AF, Techer R, Croyal M, Swietek MJ, Meilhac O, Amarenco P, Lambert G. Lipoprotein(a): A Residual Cardiovascular Risk Factor in Statin-Treated Stroke Survivors: Insights From the SPARCL Trial. JACC Adv. 2023 Aug 22;2(7):100557. doi: 10.1016/j.jacadv.2023.100557. eCollection 2023 Sep. |
| 32194196 | Derived | Szarek M, Amarenco P, Callahan A, DeMicco D, Fayyad R, Goldstein LB, Laskey R, Sillesen H, Welch KM; SPARCL Committees and Investigators. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. J Am Coll Cardiol. 2020 May 5;75(17):2110-2118. doi: 10.1016/j.jacc.2020.03.015. Epub 2020 Mar 16. |
| 31020900 | Derived | Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827. |
| 29114094 | Derived | Ganz P, Amarenco P, Goldstein LB, Sillesen H, Bao W, Preston GM, Welch KMA; SPARCL Steering Committee. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. Stroke. 2017 Dec;48(12):3223-3231. doi: 10.1161/STROKEAHA.117.017965. Epub 2017 Nov 7. |
| 28081824 | Derived | Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; SPARCL Trial Investigators. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. J Am Coll Cardiol. 2017 Jan 17;69(2):147-158. doi: 10.1016/j.jacc.2016.10.057. |
| 25147328 | Derived | Amarenco P, Callahan A 3rd, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KM, Wilson DJ, Zivin JA. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014 Oct;45(10):2974-82. doi: 10.1161/STROKEAHA.114.005832. Epub 2014 Aug 21. |
| 24582273 | Derived | Ovbiagele B, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A 3rd, Hennerici MG, Zivin J, Welch KM; SPARCL Investigators. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. J Stroke Cerebrovasc Dis. 2014 Apr;23(4):778-84. doi: 10.1016/j.jstrokecerebrovasdis.2013.12.001. Epub 2014 Feb 24. |
| 21670382 | Derived | Callahan A, Amarenco P, Goldstein LB, Sillesen H, Messig M, Samsa GP, Altafullah I, Ledbetter LY, MacLeod MJ, Scott R, Hennerici M, Zivin JA, Welch KM; SPARCL Investigators. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Arch Neurol. 2011 Oct;68(10):1245-51. doi: 10.1001/archneurol.2011.146. Epub 2011 Jun 13. |
| 21570534 | Derived | Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May;161(5):993-9. doi: 10.1016/j.ahj.2011.02.002. |
| 20110538 | Derived | Amarenco P, Goldstein LB, Sillesen H, Benavente O, Zweifler RM, Callahan A 3rd, Hennerici MG, Zivin JA, Welch KM; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2010 Mar;41(3):426-30. doi: 10.1161/STROKEAHA.109.564781. Epub 2010 Jan 28. |
| 18962621 | Derived | Amarenco P, Goldstein LB, Callahan A 3rd, Sillesen H, Hennerici MG, O'Neill BJ, Rudolph AE, Simunovic L, Zivin JA, Welch KM; SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009 Jun;204(2):515-20. doi: 10.1016/j.atherosclerosis.2008.09.008. Epub 2008 Sep 18. |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000069059 | Atorvastatin |
| ID | Term |
|---|---|
| D011758 | Pyrroles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006538 | Heptanoic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided